MARKER THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
MARKER THERAPEUTICS, INC. (MRKR) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $130.73 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-03-18
- MARKER THERAPEUTICS, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2025 was $130.73K, a 86.15% decline from fiscal 2024.
- MARKER THERAPEUTICS, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $943.80K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $130.73K 10-K · filed 2026-03-18 |
| 2024-12-31 | $943.80K 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |